

About Deep Pharma Intelligence

Deep Pharma Intelligence (DPI) is a leading UK-based strategic and investment intelligence agency focused on the emerging markets in the Pharmaceutical, Biotech, and Healthcare Tech industries.

Deep Pharma Intelligence is a joint venture created by **Deep Knowledge Analytics Pharma Division** and **BPT Analytics (BiopharmaTrend)** – two highly specialized think tanks in the area of biotech innovation profiling, business intelligence, and biotech investment advisory. The company is dedicated to producing powerful data mining and visualization systems, interactive analytics tools, and industry reports offering deep technical insights, business intelligence, and strategic guidance in the high growth and significant opportunity areas of the pharmaceutical industry, including artificial intelligence (AI) in drug discovery, emerging therapeutic targets and drug modalities, new therapies and technologies, promising startups, and more.

Our Value Proposition:

Open Access and Proprietary Reports

Deep Pharma Intelligence is producing regular open access reports covering emerging bio-pharmaceutical markets – technologies, innovations, companies, and trends.

Our clients and partners can enjoy access to proprietary reports, featuring additional in-depth research conducted by our team on regular basis.

IT-Platform and Big Data Analytics Dashboard

Our company is building a sophisticated cloud-based engine for advanced market and business intelligence in the pharmaceutical and healthcare industries. It includes data mining engine, infrastructure for expert data curation, and advanced visualization dashboards, including mindmaps, knowledge graphs, and 3-dimensional visualizations.

Visit our prototype dashboard to learn more:
<https://www.deep-pharma.tech/dashboard>

Strategic Consulting and Investment Advisory

Deep Pharma Intelligence offers a comprehensive range of consulting services, including comprehensive support for growth and investment decision making in the bio-pharmaceutical industry and related areas. It includes a wide range of services from market and competitor research, technology scouting and due diligence, to investment landscape profiling and comprehensive analytics support for investment decision-making.




Investment Digest “Artificial Intelligence for Drug Discovery, Biomarker Development and Advanced R&D Landscape Overview in Asia 2021”

The 50-page report offers the bird’s eye view of the investment activity in the area of AI application for drug design, clinical research, and other biotech areas of high growth potential. It is an investor-oriented distillate of our landmark 130-page analytical report, covering **1000+** pharmaceutical entities, including **240+ startups**, **600+ investors**, **90+ corporations** and **35 R&D centers**.

The Investment Digest is supported by our Big Data analytics Dashboard and IT-platform, offering advanced market intelligence, interactive mindmaps, benchmarking for companies, investors and technologies, competitive and SWOT analysis and more.

Some of the key takeaways from this digest include:

- The segment of pharmaceutical AI continues consolidation;
- Asian AI in pharma market is currently in its developing phase and demonstrates rapid growth;
- Some of Asian AI pharma companies are expected to initialize IPO in 2021 and 2022;
- Big pharma and contract research organizations increasingly compete for AI partnerships;
- COVID-19 pandemics appears to be a positive catalyst for the acceleration of the AI adoption.



- Number of corporations
- Number of AI companies
- Number of investors

Industry Growth

AI for Drug Discovery in Asia Overview

